All In Biotech

NDA 216793 · Janssen Biotech

Akeega

Abiraterone Acetate, Niraparib Tosylate · Oral

Priority review

Last checked: Nov 20, 2026Latest source record: Dec 12, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Aug 11, 2023

Approved uses

2

Original approval plus efficacy supplements

Registered trials

415

71 Phase 3, 75 recruiting

FAERS reports

62

45 serious, 12 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 18, 2025.

AKEEGA with prednisone is indicated for the treatment of adult patients with deleterious or suspected deleterious BRCA2 -mutated ( BRCA2 m) metastatic castration-sensitive prostate cancer (mCSPC). AKEEGA with prednisone is indicated for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved test for AKEEGA [see Dosage and Administration (2.1) ] . AKEEGA is a combination of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with: deleterious or suspected deleterious BRCA2 -mutated ( BRCA2 m) metastatic castration-sensitive prostate cancer (mCSPC). deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved test for AKEEGA. ( 1 , 2.1 )

Mechanism: Niraparib is an inhibitor of PARP enzymes, including PARP-1 and PARP-2, that play a role in DNA repair. In vitro studies have shown that niraparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis, and cell death. Increased niraparib‑induced cytotoxicity was observed in tumor cell lines with or without deficiencies in BRCA1/2 . Niraparib decreased tumor growth in mouse xenograft models of human cancer cell lines with deficiencies in BRCA1/2 and in human patient‑derived xenograft tumor models...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • AKEEGA · ABIRATERONE ACETATE 500MG; NIRAPARIB TOSYLATE EQ 100MG BASE · TABLET, ORAL · Prescription
  • AKEEGA · ABIRATERONE ACETATE 500MG; NIRAPARIB TOSYLATE EQ 50MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Abiraterone" as an intervention, any sponsor and status, largest first.

All 415 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use6
  • constipation4
  • decreased appetite4
  • fatigue4
  • nausea4
  • product ineffective for unapproved use4
  • prostatic specific antigen increased4
  • abdominal pain upper3
  • blood pressure increased3
  • death3
  • dizziness3
  • drug ineffective3

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202425
202516
202621

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Akeega (Niraparib/Abiraterone)

2024 spending

$5.7M

Beneficiaries

74

317 claims

Per beneficiary

$77,684

$308.19 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$566,563
2024$5,748,652

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 603 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.